Efficacy, safety and predictive biomarker of third‐generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia
3G-TKI with azacitidine is an effective and safe therapy providing more chance to receive a transplantation for CML in myeloid blast phase. Potential biomarkers associated with outcomes were identified.
Authors
- S. Zhao (ORCID: https://orcid.org/0009-0000-2175-0175)
- Chuan Yan (ORCID: https://orcid.org/0000-0003-4855-1912)
- Zong-Hu Li
- Robert Peter Gale (ORCID: https://orcid.org/0000-0002-9156-1676)
- Mei Bao
- Lu Yu (ORCID: https://orcid.org/0000-0002-0256-3275)
- Fang Ye (ORCID: https://orcid.org/0000-0002-1322-7365)
- Qian Jiang (ORCID: https://orcid.org/0000-0001-7131-0522)
- Xuan Zhang (ORCID: https://orcid.org/0000-0001-6274-0598)
- Xiao Jun Huang (ORCID: https://orcid.org/0000-0003-1906-5819)
Institutions
- Peking University (CN)
- Kingmed Diagnostics (CN)
- Peking University People's Hospital (CN)
- Beijing Chuiyangliu Hospital (CN)
- Centre for Inflammation Research (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Cancer
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1002/cncr.70166
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- National Natural Science Foundation of China